Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review

Author(s): Navid Omidkhoda, Farveh Vakilian*, Amir H. Mohammadpour*, Thozhukat Sathyapalan, Amirhossein Sahebkar*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 31 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

There is an increasing number of therapeutic agents being developed for the treatment of pulmonary artery hypertension (PAH) which is a condition characterized by raised pulmonary artery pressure and right heart failure. Despite our better understanding of the pathophysiology of PAH, the treatment outcomes are still suboptimal. There is growing evidence suggesting the role of increases in the levels of aldosterone, which is a mineralocorticoid hormone, in the pathophysiology of PAH; however, the extent to which hyperaldosteronism is associated with PAH in patients is unclear. There are also a few studies assessing the effects of mineralocorticoid receptor antagonists (MRA) in PAH. MRAs are a recognized treatment for heart failure and hypertension. In this review, we focus on the relationship between aldosterone level in patients with PAH and right ventricular failure and the effect of MRAs on the PAH severity.

Keywords: Right ventricular failure, pulmonary arterial hypertension, aldosterone, mineralocorticoid receptor antagonist, therapeutic agents, pathophysiology.

[1]
Badesch DB, Champion HC, Sanchez MAG, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(1)(Suppl.): S55-66.
[http://dx.doi.org/10.1016/j.jacc.2009.04.011] [PMID: 19555859]
[2]
Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(1)(Suppl.): S43-54.
[http://dx.doi.org/10.1016/j.jacc.2009.04.012] [PMID: 19555858]
[3]
Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16(1): 13-8.
[http://dx.doi.org/10.1097/00019501-200502000-00003] [PMID: 15654194]
[4]
Hemnes AR, Champion HC. Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract Suppl 2008; 62(160): 11-9.
[http://dx.doi.org/10.1111/j.1742-1241.2008.01812.x] [PMID: 18638171]
[5]
Sysol J, Machado R. Classification and pathophysiology of pulmonary hypertension. Continuing Cardiology Education 2018; 4: 2-12.
[http://dx.doi.org/10.1002/cce2.71]
[6]
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest 2010; 137(2): 376-87.
[http://dx.doi.org/10.1378/chest.09-1140] [PMID: 19837821]
[7]
Pugh ME, Hemnes AR. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond) 2010; 6(2): 285-96.
[http://dx.doi.org/10.2217/WHE.09.88] [PMID: 20187732]
[8]
Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail 2013; 15(3): 277-83.
[http://dx.doi.org/10.1093/eurjhf/hfs173] [PMID: 23111998]
[9]
Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46(6): 1227-35.
[http://dx.doi.org/10.1161/01.HYP.0000193502.77417.17] [PMID: 16286565]
[10]
Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285(39): 29932-40.
[http://dx.doi.org/10.1074/jbc.M110.131342] [PMID: 20650892]
[11]
Pitt B, Remme W, Zannad F, et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309-21.
[http://dx.doi.org/10.1056/NEJMoa030207] [PMID: 12668699]
[12]
Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709-17.
[http://dx.doi.org/10.1056/NEJM199909023411001] [PMID: 10471456]
[13]
Bendtzen K, Hansen PR, Rieneck K. Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134(1): 151-8.
[http://dx.doi.org/10.1046/j.1365-2249.2003.02249.x] [PMID: 12974768]
[14]
Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 2004; 91(2-3): 87-91.
[http://dx.doi.org/10.1016/j.imlet.2003.11.008] [PMID: 15019274]
[15]
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142(2): 448-56.
[http://dx.doi.org/10.1378/chest.11-1460] [PMID: 22281797]
[16]
Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000; 162(4 Pt 1): 1577-86.
[http://dx.doi.org/10.1164/ajrccm.162.4.9912131] [PMID: 11029379]
[17]
Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2013; 304(10): L678-88.
[http://dx.doi.org/10.1152/ajplung.00300.2012] [PMID: 23457185]
[18]
Maron BA, Zhang Y-Y, White K, et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 2012; 126(8): 963-74.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.094722] [PMID: 22787113]
[19]
Borgdorff MA, Bartelds B, Dickinson MG, Steendijk P, Berger RM. A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Int J Cardiol 2013; 169(3): 183-9.
[http://dx.doi.org/10.1016/j.ijcard.2013.08.102] [PMID: 24067600]
[20]
Nishi I, Kawano S, Misaki M, et al. Addition of spironolactone to an angiotensin-converting enzyme inhibitor decreases lung congestion and edema in Dahl hypertensive rats. Heart Vessels 2006; 21(4): 251-5.
[http://dx.doi.org/10.1007/s00380-005-0898-5] [PMID: 16865302]
[21]
Boehm M, Arnold N, Braithwaite A, et al. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulm Med 2018; 18(1): 41.
[http://dx.doi.org/10.1186/s12890-018-0604-x] [PMID: 29499691]
[22]
Lieber GB, Fernandez X, Mingo GG, et al. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models. Eur J Pharmacol 2013; 718(1-3): 290-8.
[http://dx.doi.org/10.1016/j.ejphar.2013.08.019] [PMID: 24012780]
[23]
Maron BA, Oldham WM, Chan SY, et al. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation 2014; 130(2): 168-79.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007690] [PMID: 25001622]
[24]
Yamanaka R, Otsuka F, Nakamura K, et al. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. Hypertens Res 2010; 33(5): 435-45.
[http://dx.doi.org/10.1038/hr.2010.16] [PMID: 20186146]
[25]
Elinoff JM, Chen LY, Dougherty EJ, et al. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling. Cardiovasc Res 2018; 114(1): 65-76.
[http://dx.doi.org/10.1093/cvr/cvx198] [PMID: 29036418]
[26]
Aghamohammadzadeh R, Zhang YY, Stephens TE, et al. Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB J 2016; 30(7): 2511-27.
[http://dx.doi.org/10.1096/fj.201500042] [PMID: 27006450]
[27]
Safdar Z, Thakur A, Singh S, et al. Circulating aldosterone levels and disease severity in pulmonary arterial hypertension. J Pulm Respir Med 2015; 5(5): 5.
[http://dx.doi.org/10.4172/2161-105X.1000295] [PMID: 27170847]
[28]
Martyniuk TV, Chazova IE, Masenko VP, Volkov VN, Belenkov IuN. Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension Ter Arkh 1998; 70(4): 33-6.
[PMID: 9612899]
[29]
Erne P, Müller A, Rossi GP, et al. Aldosterone and renin in cardiac patients referred for catheterization. Medicine (Baltimore) 2017; 96(25)e7282
[http://dx.doi.org/10.1097/MD.0000000000007282] [PMID: 28640140]
[30]
Calvier L, Legchenko E, Grimm L, et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart 2016; 102(5): 390-6.
[http://dx.doi.org/10.1136/heartjnl-2015-308365] [PMID: 26869635]
[31]
Elinoff JM, Rame JE, Forfia PR, et al. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. Trials 2013; 14: 91.
[http://dx.doi.org/10.1186/1745-6215-14-91] [PMID: 23547564]
[32]
Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013; 112(5): 720-5.
[http://dx.doi.org/10.1016/j.amjcard.2013.04.051] [PMID: 23751938]
[33]
Andersson C, Hansen PW, Steffensen IE, et al. Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure - A danish nationwide registry-based study. Eur J Intern Med 2019; 63: 56-61.
[http://dx.doi.org/10.1016/j.ejim.2019.02.014] [PMID: 30833208]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 31
Year: 2020
Published on: 23 May, 2020
Page: [3862 - 3870]
Pages: 9
DOI: 10.2174/1381612826666200523171137
Price: $65

Article Metrics

PDF: 25
HTML: 3